title: Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
abstract: BACKGROUND
  Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.
  
  
  METHODS
  This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.
  
  
  RESULTS
  Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤ 59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.
  
  
  CONCLUSIONS
  Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.
authors.affiliation: Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL-D4555, Collegeville, PA 19426-3930, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Strutton
authors.forename: Raymond A
authors.initials: RA
authors.lastname: Farkouh
authors.forename: Jaime L
authors.initials: JL
authors.lastname: Rubin
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: McGarry
authors.forename: Paul M
authors.initials: PM
authors.lastname: Loiacono
authors.forename: Keith P
authors.initials: KP
authors.lastname: Klugman
authors.forename: Steven I
authors.initials: SI
authors.lastname: Pelton
authors.forename: Kristen E
authors.initials: KE
authors.lastname: Gilmore
authors.forename: Milton C
authors.initials: MC
authors.lastname: Weinstein
mesh_terms: D002675:Child, Preschool; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D014481:United States / Q000453:epidemiology
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines